Navigation Links
Cellectis to Present at the American Society of Gene & Cell Therapy Annual Meeting
Date:5/11/2010

PARIS, May 11 /PRNewswire-FirstCall/ -- Cellectis (Alternext: ALCLS), the French genome engineering specialist, announces today that Frederic Paques, PhD, Chief Scientific Officer, has been invited to present Cellectis' approaches on vectors for meganucleases and genome surgery at the 13th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting to be held at the Marriott Wardman Park Hotel in Washington, USA, on May 19-22, 2010.

Targeted approaches have emerged today as an alternative to current random insertion strategies for gene therapy. Meganucleases, the most specific endonucleases, represent ideal tools for targeted genome editing, or genome surgery. They can induce up to 20% of gene insertion into chosen human genes. The entry of meganucleases into different cell types can be achieved by various means, including viral and non-viral vectorization.

Dr Paques will discuss "Meganucleases and Viral Vectors: Alternative or Complementary Approaches" on May 22, 2010, at 8:30AM, during an oral session on Special Considerations with Using Viral Vectors for Gene Modification of Stem Cells.

About Cellectis

Cellectis is a pioneer in the field of genome engineering. The company designs and markets innovative tools - meganucleases. These molecular scissors enable targeted modifications to DNA, with applications in the research, biomanufacturing, agrobiotechnology and therapeutic sectors.

To date, Cellectis has formed over 20 academic research partnerships and has established more than 50 agreements with pharmaceutical laboratories, seed producers and biotech companies across the world. The company holds exclusive rights to a portfolio of over 260 patents granted or pending.

Since 2007, Cellectis has been listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris and has secured over EUR 70 million in funding since inception.

More information at www.cellectis.com

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives. Such forward-looking statements are based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company's products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavorable developments in connection with these and other risks and uncertainties described, in particular, in the Company's prospectus prepared in connection with its IPO and on which the French Autorite des marches financiers ("AMF") granted its visa no. 07-023 on January 22, 2007, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.


'/>"/>
SOURCE Cellectis
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Monsanto Licenses Use of Cellectis Innovative Genome Modification Technology
2. Cellectis and Regeneron Sign an Agreement Over the use of Homologous Recombination Technology
3. Cellectis Sues Precision BioSciences for Infringement of its Patents Concerning Meganuclease Technology
4. Zymes LLC, University of Windsor and National Research Council of Canada Collaborative Research Presented at the 2010 Experimental Biology Meeting in Anaheim, California
5. BioMed Realty Trust to Webcast Company Presentation at Investor Day 2010
6. Dyadic International to Present at Rodman & Renshaw 6th Annual Global Healthcare Conference
7. Neuralstem, Inc. to Present At World Stem Cells and Regenerative Medicine Congress
8. Yongye International to Present at Upcoming Investor Conferences
9. Cardium to Present at MDB Capital Groups 2010 Bright Lights Conference
10. Talecris Biotherapeutics to Present at the Bank of America Merrill Lynch Health Care Conference
11. Brazilian Biotechnology Present at BIO 2010 Is Looking for the Worldwide Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... , April 27, 2016 ... (CSE: NSK) (OTCPink: NSKQB) ( Frankfurt ... an ihre Pressemitteilung vom 13. August 2015 die ... ihre Finanzen um zusätzliche 200.000.000 Einheiten auf 400.000.000 ... Dollar zu bringen. Davon wurden 157.900.000 Einheiten mit ...
(Date:4/27/2016)... ... 2016 , ... PathSensors, Inc., a leading environmental testing company, ... assist PathSensors in expanding the use of the company’s CANARY® technology in the ... for the detection of harmful pathogens, including a number of bacteria, viruses, toxins, ...
(Date:4/27/2016)... MedDay, a biotechnology company focused on the treatment of ... as Chairman of its Board of Directors. Catherine ... who contributed to the rapid development of the Company since ... her career in strategy consulting and investment banking in ...  She held C-Suite level roles in some of ...
(Date:4/26/2016)... ... , ... The European Patent Office (EPO) today announced that ... the European Inventor Award 2016 in the category "Non-European countries." The winners of the ... in Lisbon on June 9th. , The human capacity to walk with fluidity is ...
Breaking Biology Technology:
(Date:3/9/2016)... 9, 2016  Crossmatch ® , a leading ... today announced the addition of smart features to ... multi-factor authentication platform. New contextual and application-specific authentication ... security where it,s needed most — while minimizing ... . --> Washington, DC ...
(Date:3/3/2016)... and DE SOTO, Kansas , ... Stroke Detection Plus® to offer Oncimmune,s Early CDT®-Lung, ... and early detection of lung cancer Early ... unions and individuals. --> Early CDT®-Lung test ... individuals. --> Oncimmune, a leader in early ...
(Date:3/1/2016)... FRANCISCO , March 1, 2016  (RSAC Booth ... year, but a whopping $118 billion is lost to ... to overzealous and inaccurate fraud detection. At the RSA ... in the way companies handle authentication by devaluing the ... and behavioral analytics. --> ...
Breaking Biology News(10 mins):